Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992430 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
A Phase 3 study of Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT03992430 is a Phase 3 study of Muscular Dystrophy, Duchenne that is active but no longer recruiting, run by Sarepta Therapeutics. The registered enrollment target is 160 participants, above the 67-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03992430, a Phase 3 study of Muscular Dystrophy, Duchenne, is active but no longer recruiting, sponsored by Sarepta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.
Conditions Studied
Interventions
- DRUG Eteplirsen
Study Locations (20)
Other
- Hospital Universitario San Ignacio - Bogotá
- Instituto Neurologico de Colombia (INDEC) - Medellín
- Hospital Pablo Tobón Uribe - Medellín
- Brno Klinika detske neurologie - Brno
- Fakultni nemocnice v Motole - Prague
- Rigshospitalet Copenhagen University Hospital - Copenhagen
- Hopital Femme Mere Enfant - Bron
- Hopital Armand Trousseau - Paris
- CHRU de Strasbourg - Strasbourg
- Charité Universitätsmedizin Berlin CVK - Berlin
- Universitätsklinikum Essen - Essen
- Universitätsklinikum Freiburg - Freiburg im Breisgau
- Semmelweis Egyetem Genomikai Medicina és Ritka Betegsegek Intezete - Budapest
- Royal Institute of Child Neurosciences - Ahmedabad
- Aster RV Hospital - Bengaluru
- Nizam's Institute of Medical Sciences - Hyderabad
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of Florida - Gainesville
Georgia
- Rare Disease Research, LLC - Atlanta
Attica
- IASO Children's Hospital - Marousi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2020-07-13 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992430
The ClinicalTrials.gov registry entry for NCT03992430 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target (139% higher). The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Dystrophy, Duchenne appearing as the primary indexed condition, and to 1 intervention - of which Eteplirsen is the first listed.
NCT03992430 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT03992430 about?
NCT03992430 is a clinical study titled "A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)". Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 20...
What is the current status of trial NCT03992430?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2020-07-13. Estimated completion is 2026-10-31.
What conditions does trial NCT03992430 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Duchenne.
What interventions are being tested in trial NCT03992430?
The interventions under investigation include: Eteplirsen (DRUG).
Who is sponsoring clinical trial NCT03992430?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992430 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Attica. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Duchenne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 3
-
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.